This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Analysts' Actions: CSCO GOOG TEVA RVBD PCS

Stocks in this article: TEVA RVBD PCS BIIB ATVI CELG AAP CSCO GOOG

Riverbed downgraded at Cantor from buy to hold, Cantor Fitzgerald said. $20 price target. Core products are showing little growth.

Teva (TEVA - Get Report) downgraded at Canaccord to hold, Canaccord Genuity said. $45 price target. Company turnaround is taking longer than expected.

Trinity Industries (TRN) downgraded at UBS to neutral from buy, UBS said. $41 price target. Continued growth in tank car orders increasingly challenging.

Westlake Chemical (WLK) upgraded at UBS to neutral from sell, UBS said. $90 price target. Softer ethane pricing outlook.

STOCK COMMENTS / EPS CHANGES

Biogen Idec (BIIB - Get Report) numbers increased at Credit Suisse. BIIB estimates were raised through 2016, Credit Suisse said. Tysabri deal should add to earnings. Outperform rating and new $185 price target.

Cigna (CI) numbers raised at Jefferies. Shares of CI now seen reaching $71, Jefferies said. Estimates also raised on its upward 2013 revision. Buy rating.

Cisco (CSCO) target raised at Citigroup to $24, Citigroup said. Continued execution in an improving macro environment. Buy rating.

Coinstar (CSTR) estimates, target cut at JP Morgan. CSTR estimates were reduced through 2014, JP Morgan said. Company is seeing lower sales. Neutral rating and new $51 price target.

Eastman Chemical (EMN) target raised at Jefferies. Shares of EMN now seen reaching $79, Jefferies said. Favorable pricing in 2013. Hold rating.

Google (GOOG) added to Best Ideas List at Morgan Stanley. Company can deliver 15% compound annual free cash flow growth over the next five years. $932 price target.

CarMax (KMX) numbers raised at Oppenheimer. Shares of KMX now seen reaching $46, Oppenheimer said. Estimates also raised on attractive market share growth. Outperform rating.

LinkedIn (LNKD) estimates, target raised at BMO. Shares of LNKD now seen reaching $130, according to BMO Capital. Estimates also increased, as new products are driving growth. Market Perform rating.

Microchip Technology (MCHP) numbers raised at Jefferies. Shares of MCHP now seen reaching $41, Jefferies said. Estimates also raised on fourth quarter beat. Buy rating.

Microchip estimates, target raised at Credit Suisse. Shares of MCHP now seen reaching $40, according to Credit Suisse. Estimates also increased, as the company is seeing higher core demand and benefits from acquisitions. Outperform rating.

Martin Marietta (MLM) numbers raised at Jefferies. Shares of MLM now seen reaching $114, Jefferies said. Estimates also raised stronger demand enabling fourth quarter beat. Buy rating.

NCR (NCR) estimates, target boosted at JP Morgan. Shares of NCR now seen reaching $37, according to JP Morgan. Estimates also upped, given the company's new guidance. Overweight rating.

OpenTable (OPEN) numbers lowered at Oppenheimer. Shares of OPEN now seen reaching $49, Oppenheimer said. Estimates also lowered on slowing earnings growth. Perform rating.

Patterson-UTI (PTEN) numbers upped at BMO. PTEN estimates were boosted through 2014, BMO Capital said. Company is seeing higher demand for pressure pumping. Outperform rating and new $25 price target.

>To submit a news tip, email: tips@thestreet.com.

READERS ALSO LIKE:


Follow TheStreet on Twitter and become a fan on Facebook.

This article was written by a staff member of TheStreet.
2 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,164.95 -251.90 -1.45%
S&P 500 1,994.99 -26.26 -1.30%
NASDAQ 4,635.24 -48.1670 -1.03%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs